Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure

M. Packer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The major therapeutic goals in the treatment of congestive heart failure are the relief of symptoms and the prolongation of life, but it remains unclear whether there is a relation between changes in exercise tolerance and alterations in the risk of death. Although all vasodilator and inotropic agents produce short-term haemodynamic benefits, these acute effects do not predict the long-term clinical responses to these drugs. Converting-enzyme inhibitors appear to improve symptoms and survival. A combination of hydralazine and isosorbide dinitrate produces variable effects on exercise tolerance but appears to prolong life. Catecholamines and phosphodiesterase inhibitors may reduce dyspnea and fatigue but adversely affect mortality. Calcium channel blocking drugs may exert deleterious effects on both symptoms and prognosis. α-Adrenergic blocking drugs produce no beneficial or adverse effects on clinical status or mortality. Hence, there is no consistent relation between the symptomatic and prognostic effects of drug therapy in patients with chronic heart failure. This variability makes it impossible to predict the effects of any drug on exercise tolerance or survival based on an evaluation of the agent's short-term haemodynamic effects.

Original languageEnglish (US)
Pages (from-to)105-108
Number of pages4
JournalEuropean Heart Journal
Volume9
Issue numberSUPPL. H
StatePublished - 1988

Fingerprint

Exercise Tolerance
Vasodilator Agents
Heart Failure
Survival
Hemodynamics
Life Support Care
Phosphodiesterase Inhibitors
Mortality
Calcium Channel Blockers
Enzyme Inhibitors
Pharmaceutical Preparations
Adrenergic Agents
Dyspnea
Catecholamines
Fatigue
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure. / Packer, M.

In: European Heart Journal, Vol. 9, No. SUPPL. H, 1988, p. 105-108.

Research output: Contribution to journalArticle

@article{210f2f9567a54bc894d4158739501735,
title = "Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure",
abstract = "The major therapeutic goals in the treatment of congestive heart failure are the relief of symptoms and the prolongation of life, but it remains unclear whether there is a relation between changes in exercise tolerance and alterations in the risk of death. Although all vasodilator and inotropic agents produce short-term haemodynamic benefits, these acute effects do not predict the long-term clinical responses to these drugs. Converting-enzyme inhibitors appear to improve symptoms and survival. A combination of hydralazine and isosorbide dinitrate produces variable effects on exercise tolerance but appears to prolong life. Catecholamines and phosphodiesterase inhibitors may reduce dyspnea and fatigue but adversely affect mortality. Calcium channel blocking drugs may exert deleterious effects on both symptoms and prognosis. α-Adrenergic blocking drugs produce no beneficial or adverse effects on clinical status or mortality. Hence, there is no consistent relation between the symptomatic and prognostic effects of drug therapy in patients with chronic heart failure. This variability makes it impossible to predict the effects of any drug on exercise tolerance or survival based on an evaluation of the agent's short-term haemodynamic effects.",
author = "M. Packer",
year = "1988",
language = "English (US)",
volume = "9",
pages = "105--108",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "SUPPL. H",

}

TY - JOUR

T1 - Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure

AU - Packer, M.

PY - 1988

Y1 - 1988

N2 - The major therapeutic goals in the treatment of congestive heart failure are the relief of symptoms and the prolongation of life, but it remains unclear whether there is a relation between changes in exercise tolerance and alterations in the risk of death. Although all vasodilator and inotropic agents produce short-term haemodynamic benefits, these acute effects do not predict the long-term clinical responses to these drugs. Converting-enzyme inhibitors appear to improve symptoms and survival. A combination of hydralazine and isosorbide dinitrate produces variable effects on exercise tolerance but appears to prolong life. Catecholamines and phosphodiesterase inhibitors may reduce dyspnea and fatigue but adversely affect mortality. Calcium channel blocking drugs may exert deleterious effects on both symptoms and prognosis. α-Adrenergic blocking drugs produce no beneficial or adverse effects on clinical status or mortality. Hence, there is no consistent relation between the symptomatic and prognostic effects of drug therapy in patients with chronic heart failure. This variability makes it impossible to predict the effects of any drug on exercise tolerance or survival based on an evaluation of the agent's short-term haemodynamic effects.

AB - The major therapeutic goals in the treatment of congestive heart failure are the relief of symptoms and the prolongation of life, but it remains unclear whether there is a relation between changes in exercise tolerance and alterations in the risk of death. Although all vasodilator and inotropic agents produce short-term haemodynamic benefits, these acute effects do not predict the long-term clinical responses to these drugs. Converting-enzyme inhibitors appear to improve symptoms and survival. A combination of hydralazine and isosorbide dinitrate produces variable effects on exercise tolerance but appears to prolong life. Catecholamines and phosphodiesterase inhibitors may reduce dyspnea and fatigue but adversely affect mortality. Calcium channel blocking drugs may exert deleterious effects on both symptoms and prognosis. α-Adrenergic blocking drugs produce no beneficial or adverse effects on clinical status or mortality. Hence, there is no consistent relation between the symptomatic and prognostic effects of drug therapy in patients with chronic heart failure. This variability makes it impossible to predict the effects of any drug on exercise tolerance or survival based on an evaluation of the agent's short-term haemodynamic effects.

UR - http://www.scopus.com/inward/record.url?scp=0023730285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023730285&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 105

EP - 108

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - SUPPL. H

ER -